v3.26.1
Organization, Description of Business and Summary of Significant Accounting Policies - Narrative (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Class of Stock [Line Items]          
Number of operating segments | segment     1    
Intangible asset amortization - operating expenses $ 3,200,000 $ 3,300,000 $ 6,400,000 $ 6,500,000  
Short-term investments, allowance for expected credit losses 0   0   $ 0
Deposits 1,700,000   1,700,000   1,600,000
Total revenue 150,321,000 130,164,000 289,392,000 244,637,000  
Accounts receivable 54,177,000   54,177,000   44,660,000
Other Testing Revenue          
Class of Stock [Line Items]          
Total revenue 4,500,000 1,800,000 8,700,000 2,200,000  
Biopharmaceutical and other revenue          
Class of Stock [Line Items]          
Total revenue 802,000 $ 4,303,000 1,103,000 7,887,000  
Accounts receivable 1,400,000   1,400,000   3,600,000
Deferred revenue $ 600,000   $ 600,000   $ 1,200,000
Amortization Of Intangible Assets          
Class of Stock [Line Items]          
Intangible asset amortization - operating expenses       $ 1,900,000